Edwards Lifesciences (NYSE:EW) issued an update on its second quarter 2021 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.540-0.600 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.520. The company issued revenue guidance of $1.25 billion-$1.33 billion, compared to the consensus revenue estimate of $1.25 billion.Edwards Lifesciences also updated its FY 2021 guidance to 2.070-2.270 EPS.
Shares of Edwards Lifesciences stock traded down $1.74 on Tuesday, hitting $92.89. 96,258 shares of the company were exchanged, compared to its average volume of 2,758,865. The stock has a market capitalization of $57.74 billion, a price-to-earnings ratio of 75.70, a price-to-earnings-growth ratio of 2.61 and a beta of 0.97. The company has a quick ratio of 2.61, a current ratio of 3.52 and a debt-to-equity ratio of 0.14. The company has a 50-day moving average price of $86.76 and a 200 day moving average price of $85.01. Edwards Lifesciences has a 1-year low of $66.23 and a 1-year high of $98.11.
Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Monday, April 19th. The medical research company reported $0.54 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.07. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.16 billion. Edwards Lifesciences had a net margin of 18.18% and a return on equity of 29.00%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.50 EPS. Research analysts forecast that Edwards Lifesciences will post 1.89 EPS for the current year.
A number of analysts have issued reports on EW shares. Evercore ISI raised Edwards Lifesciences from an in-line rating to an outperform rating in a research report on Monday, April 5th. Morgan Stanley upped their price objective on Edwards Lifesciences from $99.00 to $108.00 and gave the stock an overweight rating in a research report on Tuesday, April 27th. Wells Fargo & Company upped their price objective on Edwards Lifesciences from $87.00 to $93.00 and gave the stock an equal weight rating in a research report on Wednesday, April 21st. Atlantic Securities assumed coverage on shares of Edwards Lifesciences in a research note on Wednesday, April 21st. They set a neutral rating and a $85.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Edwards Lifesciences from a buy rating to a hold rating and set a $102.00 target price for the company. in a research note on Monday, April 26th. One analyst has rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of Buy and an average target price of $99.93.
In other Edwards Lifesciences news, Director Nicholas J. Valeriani sold 8,200 shares of Edwards Lifesciences stock in a transaction on Thursday, February 4th. The shares were sold at an average price of $85.21, for a total value of $698,722.00. Following the transaction, the director now owns 67,896 shares in the company, valued at approximately $5,785,418.16. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Heisz Leslie Stone sold 6,707 shares of Edwards Lifesciences stock in a transaction on Friday, April 23rd. The shares were sold at an average price of $97.52, for a total transaction of $654,066.64. Following the completion of the transaction, the director now owns 29,272 shares in the company, valued at approximately $2,854,605.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 310,003 shares of company stock worth $26,173,339. 1.48% of the stock is owned by company insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
Featured Article: What is meant by a buy rating?